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Background: The role of human papillomavirus (HPV) may be involved in the development of esophageal cancer
(EC) and the polymorphic immune response gene transporter associated with antigen processing (TAP) may be
involved in HPV persistence and subsequent cancer carcinogenesis. The current study aims to provide association
evidence for HPV with EC, to investigate TAP1 polymorphisms in EC and assess its association with HPV statuses
and EC in Kazakhs.
Methods: The HPV genotypes in 361 patients with EC and 66 controls selected from Kazakh population were
evaluated using PCR. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed
to detect two SNPs of TAP1 in 150 cases comprised of 75 HPV+ and 75 HPV- patients and 283 pure ethnic population
of Kazakh and evaluate their associations with susceptibility to EC. A case-to-case comparison based on the genotyping
results was conducted to address the function of TAP1 variants in the involvement of HPV.
Results: The presence of four HPV genotypes in EC tissues ― including HPV 16, 18, 31, 45― was significantly higher
at 64.6 % than those in controls at 18.2 % (P < 0.001). Such presence was strongly associated with increased risk of EC
(OR 8.196; 95 % CI 4.280–15.964). The infection of HPV16, and multi-infection of 16 and 18 significantly increase the risk
for developing EC (OR 4.616, 95 % CI 2.099–10.151; and OR 6.029, 95 % CI 1.395–26.057 respectively). Heterozygote of
TAP1 D637G had a significantly higher risk for developing EC (OR 1.626; 95 % CI 1.080–2.449). The odds ratio for HPV
infection was significantly lower among carriers of TAP1 D637G polymorphism (OR 0.281; 95 % CI 0.144–0.551).
Conclusions: HPV infection exhibits a strong positive association with the risk of EC in Kazakhs. Heterozygote of TAP1
D637G decreases susceptibility to HPV infection in patients with EC but increases susceptibility to EC among the Kazakh
populations.
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Esophageal cancer, one of the most aggressive malignan-
cies originating in the gastrointestinal tract, as well as, the
sixth most frequent cause of cancer-related death world-
wide, with wide geographic, ethnic or social cultural vari-
ation, results in more than 400,000 deaths annually [1, 2].
The two main histological types of esophageal cancer:
esophageal squamous cell carcinoma (ESCC) and esopha-
geal adenocarcinoma (EAC), of which the former is pre-
dominant type accounting for more than 80 % in China
[3]. Comparing with other areas and ethnic groups of
China, the Kazakh population, a nomadic tribe and
mainly residing in the northwest of Xinjiang Province,
shows high incidence and mortality of ESCC, with the
highest age-adjusted mortality of 90.7/100,000 among
all of the ethnic populations in Xinjiang [4]. Epidemio-
logical studies have shown that heavy smoking and al-
cohol consumption, the main environmental risk
factors for ESCC in Europe and North America [5–7],
however seem to be minor risk factors for ESCC in the
high-incidence areas in China [8, 9]. Therefore, other
risk factors should be considered to explain the high in-
cidence of ESCC in these areas.
Human papillomavirus (HPV), a nonenveloped double-
stranded DNA virus with more than 120 kinds of subtypes
have been separated, including more than 80 kinds of
DNA sequencing, is a crucial tumor-related virus.
HPV DNA has been detected in more than 90 % of
cervical cancer specimens [10]. Notably, several stud-
ies indicated that HPV infection was found in extra
genital cancers, such as 30 % of the human head and
neck cancer and oral and oropharyngeal squamous
cell carcinoma [11, 12], however, the etiological impli-
cation of HPV in these malignancies remains contro-
versial [13]. In 1982, the association between HPV
and EC was first reported that HPV infection caused
pathological lesions in EC specimens [14]. Subsequent
studies conducted in different geographic areas and
ethnic groups, such as Han ethnic group in eastern
China (Linxian and Anyang in Henan Province, Cixian in
Hebei, Yangcheng in Shanxi and the northern Jiangsu
province) and Kazakh minority residing in the northwest
part of China, have shown large variations in the preva-
lence of HPV among EC patients, ranging from 0 to 100 %
[15–20], which brought about opposite conclusions in the
influence of HPV on the development of EC. The dis-
crepancies may be generally attributed to the small size
of the samples, differences in immunological and mo-
lecular methods, as well as inter-laboratory variability
in sample collection and handling [21, 22]. In previous
studies, HPV infection rate in EC in Kazakh patients
varied from 18.6 to 41.1 % [19, 23, 24]. It comes up that
the role of HPV infection in esophageal epithelium car-
cinogenesis is puzzling.However, HPV alone is not sufficient to induce malig-
nant transformation. The long-held theory of immune sur-
veillance indicates that the alert immune system
permanently prevent the growth of cancer by recognizing
and eliminating the vast majority of incipient cancer cells
and thus nascent tumors [25]. The major histocompatibil-
ity complex (MHC) plays a major role in the immune re-
sponse against viral infections and transformed cells by
presenting peptide antigens to cytotoxic T lymphocytes
[26–28]. The transporter associated with antigen process-
ing (TAP), whose genes are encoded in the MHC class II
region of chromosome 6, is a critical component of the
major histocompatibility complex (MHC) class I antigen
presentation [29, 30]. Transporter associated with antigen
processing is composed of two integral membrane pro-
teins, TAP1 and TAP2, TAP1 functions by providing a
supply of candidate peptides to the MHC-I molecules
within the peptide loading complex and by transporting
antigen peptides from the cytoplasm into the endoplasmic
reticulum, [31, 32]. Regarding EC, the loss of expression of
MHC class I and TAP1 has been reported to render some
tumor cells to escape the immune surveillance and con-
tribute to the clinical course of EC [33].
Some single nucleotide polymorphisms (SNPs) of TAP
gene appear to influence the antigen peptide selection
and transport process, and have been confirmed to be
susceptible to various human diseases including immune
diseases [34–36], infectious diseases [37–40] and tumors
[41–43]. However, there has been only one study on the
association of TAP polymorphisms and EC [44]. In this
study, five gene polymorphisms including two at TAP1
and three at TAP2 were genotyped using polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) method in 265 cases of ESCC and 357 con-
trols. The results show no significant difference between
the polymorphisms at TAP1 I333V and D637G and EC
in Anyang, Henan. Given that TAP1 plays an important
role in immune response and the polymorphisms of this
gene may result in the conformational and functional
change, and thus may affect individual’s susceptibility to
HPV infection and subsequently the HPV-associated
cancer development. What’s more, the distribution of
Codon 333 and 637 polymorphisms of TAP1 and its re-
lationship with HPV infection and EC remains unknown
among the Kazakh population. Therefore the two poten-
tially functional SNPs of this immune response gene to
HPV must be investigated to define individuals with
higher risk of developing malignant disease.
Therefore, the present study is employed to identify
whether HPV infection is linked to the etiology of EC
using PCR in 316 EC specimens and 66 biopsy samples
of normal esophageal squamous epithelium from the
Yili, an area with high incidence of EC. Additionally, 150
paraffin-embeded tumor specimens and 283 matched
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ation between TAP1 polymorphisms and risk of EC in this
ethnic and to accumulate evidence regarding the potential
role of TAP polymorphisms in the disease. Subsequently,
a case-to-case comparison based on the genotyping results
was conducted to address the possible function of the
TAP1 variants in the involvement of HPV in Kazakh pa-
tients with EC.
Materials and methods
Specimens used for detecting HPV infection
A total of 316 EC specimens of Kazakh in formalin-fixed
paraffin-embedded archival tissues were collected from the
People’s Hospital of Xinjiang Uyghur Autonomous Region,
the First University Hospital, Shihezi University School
of Medicine and several hospitals in the Yili Kazakh
Autonomous Prefecture. The 316 cases were diagnosed
between January 1990 and March 2014, and they were
all diagnosed as ESCC. The pathological grade of tu-
mors was classified at the time of diagnosis. Patients
had received neither chemotherapy nor radiotherapy
before endoscopies and surgery. All samples were sur-
gically resected and fixed in 10 % buffered-formalin,
routinely processed, and paraffin-embedded. The speci-
mens of Kazakh patients were all obtained from the
high-incidence areas in Xinjiang. From the patients’
medical records, we gathered data on clinical patho-
logical variables such as tumor site, invasion depth, and
distant metastasis. All cases of pathological diagnosis
for the tumor-node- metastasis (TNM) stages were evalu-
ated according to Cancer Stage Manual 7th Edition 2009
issued in 2009 by the American Joint Committee on
Cancer (AJCC/UICC). Informed consent of each pa-
tient was obtained, and study protocol was approved by
the Institutional Review Board at Shihezi University
School of Medicine. Biopsy samples of normal esopha-
geal squamous epithelium were available from 66 con-
trol patients matched for ethnicity, who were from
Kazakh-gathering place in Xinyuan, Yili and partici-
pated in the project of Early Diagnosis and Treatment
of EC in Xinjiang Province. Each control had under-
gone upper gastrointestinal endoscopy and the esopha-
geal tissue samples were confirmed as histologically
normal. At the same time, the control subjects’ corre-
sponding pathological and clinical data were gained.
The patients in this study were comprised of 187 men
and 129 women with an average age of 52.89 ±
8.923 years (ranging from 23 to 79 years). In addition, a
total of 36 men and 30 women control subjects were
matched with an average age of 50.67 ± 11.542 years
(ranging from 19 to 64 years). The difference between
cases and controls is of no significance in gender (P =
0.488) and age (t = 1.741, P = 0.083) distribution. The
cases included 106 (33.5 %) well-differentiated patients(group G1), 162 (51.3 %) moderately differentiated pa-
tients (G2), and 48 (15.2 %) poorly differentiated patients
(G3). When evaluated according to Cancer Stage Man-
ual 7th Edition 2009, the 316 ESCC cases, 48 (15.2 %)
were classified as stage I, 183 (58.0 %) as stage II, 75
(23.7 %) as stage III, and 10 (3.1 %) as stage IV. Of the
316 ESCC cases, 30 (9.5 %) were classified as T1, 158
(50.0 %) as T2, 123 (38.9 %) as T3, and 5 (1.6 %) as T4.
Specimens used for testing TAP1 gene polymorphisms
The 316 Kazakh patients with EC mentioned above,
which had been tested for HPV infection, was then di-
vided into two groups (204 cases infected with HPV and
112 cases that weren’t), from both of which we selected
75 cases respectively and at random, so a total of 150
paraffin-embedded tumor specimens were used for
genotyping TAP1 gene. The 283 controls were selected
randomly from a pool of cancer-free subjects recruited
from Kazakh ethnic population in Xinyuan, Yili, who
had visited the hospital for a conventional cancer screen-
ing program. Blood samples were collected and DNA
was extracted for the genotyping of TAP1 gene. In-
formed consent was obtained from all participants in
this study.
The patients in this study were comprised of 94 men
and 56 women with an average age of 52.29 ± 9.571 years
(ranging from 23 to 75 years). In addition, a total of 154
men and 129 women control subjects were matched
with an average age of 50.25 ± 11.991 years (ranging from
21 to 72 years). The difference in gender distribution be-
tween cases and controls is of no significance (P = 0.098),
however, age distribution differs significantly between
cases and controls (t = 1.801, P = 0.072).
Detection of HPV DNA
DNA was extracted from the paraffin sections and bi-
opsy samples using standard proteinase K digestion and
a tissue DNA extraction kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. As an internal
control, all purified genomic DNA samples were success-
fully tested by polymerase chain reaction (PCR) with a hu-
man β-actin primer set (forward: 5′-CAGACACCATG
GTGCACCTGAC-3′ and reverse: 5′-CCAATAGGCAGA
GAGAGTCAGTG-3′), indicating that the quality and
quantity of DNA were suitable for detecting the presence
of HPV. The HPV infection was first determined by PCR
using non-degenerate primer set, GP 5+/6+, Forward pri-
mer: TTGGATCCTTTGTACTGTGGTAGATACTAC and
Reverse primer: TTGGATCCGAAAAATAAACTGTAAA
TCATATTC, which produce a 150 bp ragment of L1 gene
in a wide range of HPV types. For HPV 16 DNA detection,
E7 was amplified with forward primer GATGAAATAG
ATGGTCC AGC and reverse primer GCTTTGTACGCA
CAACCGAGC. For each PCR reaction, 5 μL extracted
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25 μL. The reaction was initially carried out at 95 °C for
10 min, followed by 40 cycles of denaturation at 94 °C for
30 s, annealing at 42 °C for 90 s, and extension at 72 °C for
30 s, with a final extension at 72 °C for 5 min. The ampli-
cons were then denatured and subjected to hybridization.
Assays of the samples were run in triplicate, with positive
and negative controls (CaSki cell DNA generously pro-
vided by Professor Yang Ke, Beijing Institute for Cancer
Prevention Laboratory and distilled water) (Fig. 1). β- actin
was used as a DNA control. To confirm the accuracy of
the HPV genotyping by PCR, 10 % DNA sequence of the
positive products was then identified by NCBI Blast
(Fig. 2). A 100 % match was identified between the results
of DNA sequence displayed in the Genbank and HPV
genotype detected.
Genotyping TAP1 I333V and D637G polymorphisms
DNA was extracted from the paraffin sections and blood
samples using standard proteinase K digestion and a tis-
sue DNA extraction kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. The two
previously documented polymorphisms in TAP1 coding
regions are previously documented. The primers used in
PCR to detect for Codon 333 were as follows: forward pri-
mer GCAGGTAACATC ATGTCTCG and Reverse primer:
GACAGATTGTGGGGAGAAGC, and for Codon 637
were as follows: forward primer CAGTAGTCTTGCCTT
TATCC and Reverse primer: ATGACTGCCTCACCTGT
AAC. The PCR was carried out in 25 ml reaction mixture
containing genomic 1 ml DNA, 2.5 ml 10 × PCR bufferFig. 1 Electrophoretic analysis of the HPV genotyping using PCR. (a) GP5+/G
without HPV infection; Lane 8, negative control; Lane 9, positive control; Lane
PCR results. Lane 1, 3, 5 and 6 in HPV16 infection (150 bp); Lane 2, 4 and 7 wi
Lane 10, blank control; M, molecular weight marker(100 mM Tris, pH 7.8, 100 mM NaCl, 10 mM EDTA and
0.5 % SDS), 1.8 ml of 25 mM MgCl2, 0.5 ml of 10 mM
dNTP each, 10 pmol primer and 1.5 U of Taq polymerase
(Promega, Madison, WI, USA). The reaction was initially
carried out at 94 °C for 2 min, followed by 35 rounds of
thermal cycling were in the conditions: denaturation at
94 °C for 40 s, annealing at 57.5 °C for 40s, extension
at 72 °C for 40 s and the final extension was carried out
at 72 °C for 10 min. The terminator ready sequencin
was performed in a total volume of 20 ml containing
8 ml of PCR product, 2.5 ml 10 × PCR buffer, the en-
zymes used were 7 U of Bcl1 and Acc1 for genotyping
Codon 333 and Codon 637 respectively. Cycling condi-
tions were as follows: initial denaturing 96 °C for
2 min, followed by 30 cycles at 94 °C for 10 s, 50 °C for
5 s and 60 °C for 4 min. Restriction enzyme digestion
with Bcl1 and Acc1 (Promega, Madison, WI, USA) of
the PCR product was carried out overnight and ana-
lyzed on a 3 % agarose gel. DNA products were visual-
ized by ethidium bromide staining (Fig. 3). The −333A
and −637A showed two fragments (homozygous for the
allele −333A and −637A), while its homologue −333G
and −637G was undigested and resulted in a single
band (homozygous for allele −333G and −637G). The
presence of all three fragments defined heterozygotic
individuals. To confirm the accuracy of TAP1 I333V
and D637G genotyping by PCR, 10 % DNA sequence of
the PCR products was then identified by NCBI Blast
(Fig. 4). A 100 % match was identified between the re-
sults of DNA sequence displayed in the Genbank and
HPV genotype detected.P6+ PCR. Lane 1, 2, 4, 6 and 7 in HPV infection (150 bp); Lane 3 and 4
10, blank control; M, molecular weight marker. (b) Human papillomavirus
thout HPV16 infection; Lane 8, negative control; Lane 9, positive control;
Fig. 2 Sequencing map of the genotype for the HPV L1 (a) and HPV 16E7 (b)
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All statistical analyses were performed using SPSS version
17.0, U.S. Hardy-Weinberg equilibrium in controls was
tested by chi-square tests comparing observed and ex-
pected genotype frequencies. The presence of HPV DNA
in case–control study, Clinic pathological characteristics
of HPV-positive and HPV-negative patients with ESCC,
and the differences in the distributions of genotype of
TAP1 I333V and D637G were analyzed by chi-square test.
Logistic regression models for genotype were used to
examine TAP1 I333V and D637G polymorphisms with
risk of Kazakh EC, the effects of TAP1 D637G on risk of
ESCC with different tumor depth, histological grade andFig. 3 PCR-RFLP assay for analyzing the TAP1 Codon333 and 637 polymorp
in 3 % agarose gel stained with ethidium bromide. (a) The typical genotyp
lane 2: AA genotype (274 and 156 bp); lane 3: GG genotype (430 bp). (b) T
(405,260 and 145 bp); lane 2: GG genotype (405 bp); lane 3: AA genotype (clinical stage, and the association of HPV infection with
TAP1 I333V and D637G polymorphisms in Kazakh EC.
Results were given as P values, odds ratios (ORs) and 95 %
confidence intervals (95 % CIs). All statistical analyses
were two-sided, and P < 0.05 was considered statistically
significant.
Results
Prevalence of HPV Infection in Kazakh EC Patients
Polymerase chain reaction (PCR) was employed to
screen HPV infection statuses in 361 patients with EC
and 66 controls, and the results are shown in Table 1.
The prevalence of HPV DNA was higher in EC caseshisms. PCR product was digested by restriction enzyme and visualized
es of TAP1 Codon333 A/G. Lane 1: AG genotype (430,274 and 156 bp);
he typical genotypes of TAP1 Codon637 A/G. Lane 1: AG genotype
260 and 145 bp). M, molecular weight marker
Fig. 4 Sequencing map of the genotype for the TAP1 Codon333 polymorphism (a) and TAP1 Codon637 polymorphism (b)
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P < 0.001). Four HPV genotypes were identified in both
EC tissue and normal esophageal tissue, including HPV16,
18, 31 and 45. HPV DNA was identified in 204 of 316
tumor tissue samples. There are totally 56 EC patients and
3 normal controls with HPV multi-infection. Using the un-
conditional logistic regression models, the association
between HPV infection and Kazakh patients with EC
was evaluated. Apart from HPV45, the HPV detected,
including HPV16 (OR, 3.941;95 % CI, 1.926–7.955),
HPV18 (OR, 3.390;95 % CI, 1.411–8.145) and HPV31 (OR,
3.487; 95 % CI, 1.050–11.582), exhibited a strong positive
association with the risk of EC in Kazakhs. A higher OR
value (OR, 8.196; 95 % CI, 4.280–15.964) was observed in
patients who are tested positive for HPV DNA (Table 1).
Since the high-risk HPVs, especially types 16 and 18, have
been identified as the risk factor for cervical cancer as well
as other cancers, to study further, HPV16 or/and 18 in-
fected individuals were referred as the infected subjects and
then, the association between risk of EC with HPV16 and
18 infection was assessed. The infection of HPV16, 18 and
multi-infection of the two types significantly increase the
risk for developing EC (OR 4.616, 95 % CI 2.099–10.151;
OR 4.522,95 % CI. 1.553–13.165 and OR 6.029, 95 % CI
1.395–26.057, respectively) in this area (Table 2).
Association between HPV Infection and Clinical
pathologic Characteristics of Patients with EC
To identify whether the HPV infection influences the
clinical pathologic characteristics in Kazakh patientswith EC, the association of HPV infection with nine
characteristics including age, gender, smoking, drinking,
tumor location, histological grade, depth of invasion,
lymph node metastasis and clinic stage was examined.
Our results show that no significant difference in the
nine investigated clinical pathologic characteristics is in-
dicated between the EC patients with HPV and patients
without (Table 3).
TAP1 gene polymorphisms are predictors of EC risk in
Kazakh populations
To evaluate the role of TAP1 gene polymorphisms in
the MHC class II region in the association of Kazakh
EC, two potentially functional SNPs in TAP1 were
tested. The distribution of genotypes and alleles is
significantly different between cases and controls at
TAP1 D637G (P = 0.040 and P = 0.018 respectively),
but not at TAP1 I333V (P = 0.250 and P = 0.118 re-
spectively). TAP1 D637G allele (G) is significantly
more common in patients than that in controls (P =
0.018), suggesting that the G allele is associated with
EC in Kazakh population. Logistic regression models
for genotype were derived to examine the association
between TAP1 polymorphisms and the risk of Kazakh
EC. Only TAP1 D637G polymorphism was found to
be associated with cancer risk, which was significantly
increased for carriers of at least one G allele (OR,
1.659; 95 % CI, 1.112–2.474) and heterozygote car-
riers of the variant allele G (OR, 1.626; 95 % CI,
1.080–2.449) (Table 4).
Table 1 Analysis of the association between HPV infection and Kazakh patients with esophageal carcinoma
Types Case (n = 361) Control (n = 66) χ2 OR (95 % CI)
n (%)a n (%)a
HPV L1 204 (64.6) 12 (18.2) 47.786*** 8.196 (4.28–15.964)
HPV16E7 130(41.1) 10 (15.2) 15.881*** 3.941 (1.926–7.955)
HPV18E7 80 (25.3) 6 (9.1) 8.240** 3.390 (1.411–8.145)
HPV31E7 45(14.2) 3 (4.5) 4.671* 3.487 (1.050–11.582)
HPV45E7 23(7.3) 1 (1.5) 3.080 5.102 (0.677–38.466)
Multiple infection 56(17.7) 3 (4.5) 7.258** 4.523 (1.371–14.922)
“*”represents P < 0.05, “**”indicates P < 0.01, “***”depicts P < 0.001
aBecause of the multiple infection, the total HPV-positive rate was smaller than the sum of the positive rates of each subtype
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D637G polymorphism in Kazakh patients with ESCC
To investigate the contribution of confounding factors
such as gender and age to the risk for Kazakh ESCC,
stratification analyses were conducted to evaluate the
potential association of genetic variants of the TAP1
D637G polymorphism with risk of subgroup populations
(Table 5). Interestingly, the results showed that the risk
effects of AG/GG genotypes were more evident in fe-
male subjects (OR = 2.093). No significant association
was found between TAP1 D637G polymorphism and
ESCC with respect to age (P > 0.05).
The association between PLCE1 variants and histo-
logic grade and clinical stage of ESCC was further evalu-
ated (Table 5). When the ESCC patients were divided
into 2 subgroups, T1/T2 and T3/T4, according to the
AJCC TNM classification of carcinoma of esophagus,
the carriers of AG/GG genotypes had a significantly in-
creased risk for T1/T2 ESCC (P = 0.004, OR = 2.040).
When the ESCC patients were divided into 2 subgroups,
stage I/II and stage III/IV, the combined risk genotypes
were found to be associated with stage I/II ESCC (P =
0.016, OR = 1.721).
Relation of HPV positive of Kazakh patients with EC to
TAP1 genotype
The results of genotype frequencies of the two investi-
gated TAP1 gene polymorphisms in HPV-positive and
HPV-negative patients are summarized in Table 6. The
distribution of genotypes was significantly different be-
tween patients with HPV infection and those without atTable 2 Association of HPV 16 or/and 18 infection with risk of EC
Types Case (n = 361) C
HPV16E7 HPV18E7 n (%) n
Negative Negative 138 (43.7) 5
Positive Negative 98 (31.0) 8
Negative Positive 48 (15.2) 4
Positive Positive 32 (10.1) 2
“*”represents P < 0.05, “**”indicates P < 0.01, “***”depicts P < 0.001TAP1 D637G (P < 0.001), but not at TAP1 I333V (P =
0.056). To study further, we analyze the association be-
tween TAP1 D637G polymorphisms and HPV-
associated Kazakh patients with EC. Differing from the
wild-type AA homozygote, the combined AG/GG or AG
variant genotypes were significantly associated with
HPV-positive in EC patients (OR 0.255, 95 % CI 0.127–
0.511; and OR 0.281, 95 % CI 0.144–0.551, respectively),
although the homozygous mutant type of TAP D637G
(GG) exhibited no association with HPV-positive EC pa-
tients (P = 0.691). We further evaluated the association
between the risk of genotypes of TAP1 and risk of HPV-
associated ESCC stratified by tumor depth. Interestingly,
the results showed that differences between the protect-
ive effects of heterozygote and combined genotypes of
TAP1 D637 were more significantly in T1/T2 subjects
(P = 0.004, OR = 0.028 and P = 0.006, OR = 0.283, re-
spectively) than in T3/T4 subjects (P = 0.020, OR = 0.286
and P = 0.026, OR = 0.311 respectively).
Discussion
More than one hundred HPV subtypes have been de-
scribed [45], over forty of which have been shown to be
involved in human disease, and these subtypes are trad-
itionally characterized by the sequence of their L1 gene.
The involvement of HPV in etiology of EC has drawn
interest in the past three decades since Syrjanen first
found 40 % of EC patients had similar histological
changes to the genital warts in reproductive tract in
1982 [14]. The majority of studies have identified HPV
in ESCC samples, with infection rates ranging from 17.1ontrol (n = 66) χ2 OR (95 % CI)
(%)
2 (78.8) 1.000
(12.1) 16.541*** 4.616 (2.099–10.151)
(6.0) 10.063** 4.522 (1.553–13.166)
(3.0) 7.277** 6.029 (1.395–26.057)
Table 3 Clinic pathological characteristics of HPV-positive and HPV-negative patients with ESCC
Characteristics Number HPV+ Patients n = 204 HPV− Patients n = 112 χ2 P value
n (%) n (%)
Age (years), mean ± SD 316 53.01 ± 8.202 52.67 ± 10.141 0.746a
Age (years) 0.301 0,584
<55 173 114 (65.9) 59 (34.1)
≥55 113 90 (62.9) 53 (37.1)
Gender 2.692 0,101
Male 187 127 (67.9) 60 (32.1)
Female 129 76 (58.9) 53 (41.1)
Smoking 0.081 0.775
Yes 82 54 (65.9) 28 (34.1)
No 234 150 (64.1) 84 (35.9)
Drinking 2.149 0.143
Yes 65 47 (72.3) 18 (27.7)
No 251 157 (62.5) 94 (37.5)
Location of the tumor 1.311 0.519
The upper thoracic portion 19 10 (52.6) 9 (47.4)
The mid-thoracic portion 170 112 (65.9) 58 (34.1)
The lower thoracic portion 127 82 (64.6) 45 (35.4)
Histologic grade 0.331 0.848
Well-differentiated (G1) 106 67 (63.2) 39 (36.8)
Moderately differentiated (G2) 162 107 (66.0) 55 (34.0)
Poorly differentiated (G3) 48 30 (62.5) 18 (37.5)
Depth of invasion 0320 0.572
T1/T2 188 119 (63.3) 69 (36.7)
T3/T4 128 85 (66.4) 43 (33.6)
Lymph node metastasis 1.127 0.288
No 193 129 (66.8) 64 (33.2)
Yes 123 75 (61.0) 48 (39.0)
Clinical stage 1.847 0.174
stage I/II 231 144 (62.3) 87 (37.7)
stage III/IV 85 60 (70.6) 25 (29.4)
aStudent’s test
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gene. One study reported an infection rate of 100 %,
which was determined by detection of the HPV16 E6
and E7 genes in early cancer cases in a high-risk area
using PCR and ISH in Anyang, Henan [47]. While a re-
cent study in east China, in which 23 different HPV
types was screened using a human papillomavirus geno-
typing kit and the P16INK4a protein was detected using
immunohistochemistry (ISH), shows the absence of hu-
man papillomavirus in EC [20]. These two extreme
values may best illustrated that the incidence of HPV
infection in EC varies from the high-incidence to the
low-incidence areas [15, 17, 22, 47–51], which is not in
accordance with HPV infection in cervical carcinoma.This finding suggests that HPV infection exerts a com-
plex effect on carcinogenesis of the EC.
The PCR method was adopted to assess prevalence of
four high-risk HPV in the 361 Kazakh patients with EC
and 66 cancer-free controls obtained from several hospi-
tals between 1990 and 2014 in the Kazakh Autonomous
Prefecture of Xinjiang, an area with high incidence of
EC located in northwestern China. The significantly high
prevalence of HPV in the Kazakh patients with EC indi-
cated that HPV infection significantly affect the carcino-
genesis of the EC in Kazakh population (64.6 % vs.
18.2 %, P < 0.001). It has been shown that human papil-
loma virus is found frequently in ESCCs in high inci-
dence areas. What’s more, the frequency of HPV
Table 4 Association of TAP1 gene polymorphisms with risk of Kazakh ESCC
Genotype or allele Case n (%) Control n (%) P value OR (95 % CI)
TAP1 D637G
AAa 73 (48.7) 173 (61.1) 1.000 (reference)
AG 70 (46.7) 102 (36.1) 0.019 1.626 (1.080–2.449)
GG 7 (4.7) 8 (2.8) 0.246b 2.074 (0.725–5.930)
Combined variant genotypes
AG + GG 77 (51.3) 110 (38.9) 0.013 1.659 (1.112–2.474)
Aa 216 (72.0) 448 (79.2) 1.000 (reference)
G 84 (28.0) 118 (20.8) 0.018 1.477 (1.068–2.040)
TAP1 I333V
AAa 82 (54.7) 134 (47.3) 1.000 (reference)
AG 62 (41.3) 130 (46.0) 0.232 0.780 (0.518–1.173)
GG 6 (4.0) 19 (6.7) 0.170 0.516 (0.198–1.345)
Combined variant genotypes
AG + GG 68 (45.3) 149 (52.7) 0.112 0.724 (0.486–1.079)
Aa 226 (72.0) 398 (70.3) 1.000 (reference)
G 74 (24.7) 168 (29.7) 0.118 0.776 (0.564–1.067)
aReference group
bFisher’s exact test
Table 5 Correlations of clinicopathological parameters and TAP1 D637G polymorphism in Kazakh patients with ESCC
Parameters AA AG/GG OR (95 % CI)
(Cases/controls) (Cases/controls)
Gendera
Male 48/92 46/62 1.422 (0.848–2.385)
Female 25/81 31/48 2.093 (1.107–3.954)*
Agea
≤52 30/91 30/60 1.517 (0.831–2.769)
>52 43/82 37/50 1.411 (0804–2.478)
Tumor depthb
T1/T2 37/173 48/110 2.040 (1.249–3.333)**
T3/T4 36/173 29/110 1.267 (0.735–2.184)
Histologic grade (G)b
G1 27/173 27/110 1.573 (0.877–2.822)
G2 38/173 40/110 1.656 (0.999–2.741)
G3 8/173 10/110 1.966 (0.753–5134)
Clinical stageb
I/II 53/173 58/110 1.721 (1.106–2.679)*
III/IV 20/173 19/110 1.494 (0.763–2.925)
We consider the common homozygotes of TAP1 as ORs of 1.000 for the reference genotype
“*”represents P < 0.05, “**”indicates P < 0.01, “***”depicts P < 0.001
aStratification analysis to evaluate the effects of variant genotypes on the risk of ESCC by age and sex
bLogistic regression analysis for the effects of TAP1 variants on risk of ESCC with different tumor depth, histologic grade and clinical stage through logistic
regression analyses. G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated
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Table 6 Stratification analysis to evaluate the association of HPV positive patients with TAP1 polymorphisms in Kazakh ESCC by
tumor depth
Parameters TAP1 D637G (HPV+/HPV- patients) OR (95 % CI) TAP1 I333V (HPV+/HPV- patients) OR (95 % CI)
AAa AG/GG AAa AG/GG
Tumor depth
T1/T2 21/16 13/35 0.283 (0.114–0.703)** 23/27 11/24 0.538 (0.218–1.330)
T3/T4 27/9 14/15 0.311 (0.109–0.888)* 21/11 20/13 0.806 (0.294–2.212)
T1-T4 48/25 48/25 0.281 (0.144–0.551)*** 44/38 31/37 0.724 (0.380–1.380)
“*”represents P < 0.05, “**”indicates P < 0.01, “***”depicts P < 0.001
aReference group. We consider the common homozygotes of TAP1 as ORs of 1.00 for the reference genotype
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much higher than the average rate from a systematic re-
view and a formal meta-analysis of the literature on
HPV detection in 10,234 EC cases from 1954 to 2012
[52]. Additionally, our present study showed the inci-
dence of HPV16 infection in Kazakh EC patients
(41.1 %) was significantly higher than in the control
group (15.2 %), and, it has been proposed that HPV16
infection may play a role in esophageal carcinogenesis. A
similar observation was also revealed in previous studies
in Xinjiang Kazakhs [23, 53]. Nevertheless, some studies
demonstrate no relationship between HPV infection and
EC, which may reflect discrepancy of different race, dif-
ferent ethnic and different region. In our study, strict
quality controls on the object and method of the study
was performed strictly. Therefore, we can confirm that
HPV infection is one of the important factors in high in-
cidence of Xinjiang ethnic Kazakh EC.
The data confirmed no significant association between
the presence of HPV and the histological grade of EC.
While in certain reports, well-differentiated tumors
tended to have either HPV16 or HPV16/6 infection, sug-
gesting that HPV can initiate the development of EC and
explaining the higher survival rate indicated in HPV-
positive patients with EC [13, 19]. Nevertheless, other
study reported that a positive HPV16/18 rate and viral
load were more often in poorly differentiated EC cases,
although no significant correlation was confirmed [24].
The discrepant results in the literatures may be attrib-
uted to the difference in detection methods, sample size,
and patient heterogeneity because of the variety of eth-
nicities in the sample although the samples cases were
obtained from the same region. Thus, the conclusions
concerning the influence of HPV on various differenti-
ation of EC warrant confirmation.
Host factors such as the immune systems and genetic
factors also seem to be important factors in HPV persist-
ence and subsequent cancer carcinogenesis [52, 54]. The
polymorphisms of TAP1 genes may result in the conform-
ational and functional change of TAP, which can influence
the antigen peptide selection and transport process [55].
There are several studies on the relationship between TAP(including TAP1 and TAP2) polymorphisms and various
carcinoma, and only TAP1 polymorphisms have been con-
firmed to be susceptible to various tumor types. One study
shows that no significant difference in genotype distribu-
tion of TAP1 and TAP2 polymorphisms was observed in
women with cervical intraepithelial neoplasm (CIN) and
controls [56], and a similar study conducted in India suc-
ceeded to reproduce this observation [57], however, in an-
other similar study, significant differences in allele
distribution between women with high-grade cervical neo-
plasm (CIN II or III) and women without was seen for
both TAP1 I333V (P = 0.02) and TAP1 D637G (P = 0.01)
[58]. In addition, G allele at TAP1 Codon 637 is associated
with nasopharyngeal carcinoma (NPC) in Han population
in Yunnan, China (OR, 1.88; 95 % CI, 1.35–2.82;
P < 0.001), and EBV pathogenesis in NPC might be
facilitated by polymorphisms in the TAP1 proteins [59].
The present case–control study has analyzed the asso-
ciation between TAP gene polymorphisms and the risk
of EC in Kazakh population in Xinjiang, China. The im-
portant finding is that the heterozygote of TAP1 D637G
(AG) genotypes were associated with a 1.626-fold higher
risk for the development of EC, whereas the GG geno-
type was not associated with the risk of developing EC,
suggesting that G allele at TAP1 D637G is a risk factor
for EC, which is contrary to the study of Cao et al [44].
The reason for this discrepancy might be due to genetic
heterogeneity between Kazakh and Han population, ac-
cording to the theory that the Han Chinese population,
though seeming homogeneous, exhibits a complicated
substructure as the genetics of different Han Chinese
populations differ greatly [60]. In the current samples,
false-positive or false-negative associations owing to
population substructure were less likely to exist, because
the carefully ascertained, relatively homogeneous case–
control samples of northwestern Kazakh belong to a sin-
gle geographic location of the province of Xinjiang. This
polymorphism has been shown to vary with ethnic and
geographical distribution. However, its influence has not
been elucidated in the Kazakh population.
Epidemiologic and molecular studies have shown that
all virus agents and the genetic factors are involved in
Zou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:70 Page 11 of 12the initiation and progression of EC [17]. Another im-
portant finding in the present study is that HPV-positive
rate is lower for patients carrying allele G at TAP1
D637G, and this provides an illustration to the theory
that TAP facilitates the detection of HPV by MHC-I
molecules and contributes to detection and eradication
of HPV despite various immune evasion mechanisms of
the virus [61].
Conclusion
Taken together the present study demonstrated that G
allele at TAP1 Codon637 decreases susceptibility to
HPV infection in patients with EC among the Kazakh
populations, however, it is associated with an increased
risk of EC in this ethnic. This finding suggests that the
polymorphism of TAP1 Codon637 exerts complicated
influence on EC in Kazakh population. However, given
that the mechanisms by which TAP1 polymorphisms
may influence the course of HPV infections remains
under investigation, further studies need to be con-
ducted to elucidate the influence of TAP1 polymor-
phisms in HPV-associated EC in the Kazakh population.
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